A phase II clinical trial of consolidation treatment with iodine I 131 tositumomab for multiple myeloma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 May 2017
At a glance
- Drugs Iodine-131 tositumomab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 03 May 2017 Planned End Date changed from 1 Jan 2017 to 1 Nov 2017.
- 17 Aug 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 14 Aug 2012 Planned end date changed from 1 Jan 2015 to 1 Jan 2017 as reported by ClinicalTrials.gov.